Newsbenzinga
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
· Published
Article summary
Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lung cancer therapy ivonescimab.
An excerpt from the original article.
Comments —
Loading comments…